News

I have Huntington disease in my family. How do I change my genes?

The associate professor of neurology and neuroscience at Weill Cornell Medicine discussed this work, and what she and her colleagues believe could be addressed by a successful effort.

In its second phase 2 trial, the therapy, also known as AMO-02, resulted in improvements in cognitive function, fatigue, and neuromuscular symptoms.

The president of the American Headache Society shared her thoughts on how preventive medicines can alter migraine treatment for the better.

People of all ages occasionally report recurrent dreams, and there is an established association between negative dreams and daytime anxiety.

The study presents direct evidence that subjective experiences of insomnia may be coupled to the REM sleep state.

Darryl De Vivo, MD, emphasized that while there's been a tremendous advance in the field of SMA, it’s important to continue tinkering around the margins to make the effective treatment increasingly better.

Zonisamide improved Parkinsonism as an adjunct to levodopa in patients with dementia with Lewy bodies in phase 3 trial.

The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.

Despite the explosion of preventive medications for migraine, a large need for acute care remains.

The Sidney Carter Professor of Neurology at Columbia University Medical Center spoke about the 127 year history of spinal muscular atrophy and how basic science has led to exciting developments.

Customizing injection sites and amounts of botulinum toxin for different presentations of essential hand tremor has been shown to avoid hand weakness.

Heidbreder further described the current understanding of the condition and what she and her colleagues have found out.

For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.

With many advancements in treatments occurring in recent years, the president of the American Headache Society urged for further research to continue to light the way.

Neurology News Network for the week of Oct. 27, 2018.

As well as showing a positive impact on patient daily living and cognitive decline, data also confirmed SIGMAR1 and COMT as biomarkers of response to the therapy.

The authors suggested that the detection and tracking of seizure cycles on a patient-specific basis should be standard in epilepsy management practices.

The Psychiatrist at Psychiatric Services Solothurn and University of Basel discussed how heart rate variability correlates with sleep stages, which may indicate nocturnal brain activity.

A phase 2 trial demonstrating a PDE-10A inhibitor to be safe but not efficacious for Huntington disease could be followed with the testing of a higher dose.

Allergan is planning a 2019 NDA submission to the FDA for its agent, ubrogepant, based on a pair of new trials.

Symptoms of sudden onset of headache and decreased balance three days earlier prompted a visit to the emergency department.

Within the defined amyloid-tau-neurodegeneration framework of Alzheimer disease, the investigational agent has displayed a hopeful effect on all 3 pieces.

Despite some mistrusting the abilities of imaging to aid in therapeutic development, a new MRI method could better inform the anatomical understanding of the striatum.

Botulinum toxin was found to improve restless leg syndrome in the largest, well-controlled study of the investigational intervention to date.

The approval and immediate launch of the product in both tablet and oral suspension offer a generic alternative to Onfi.

Under treatment, the dynamic of REM sleep related heart rate variability shows early changes during the first week, providing a promising biomarker of treatment.

New brain stimulation technology is proven effective for Parkinson in the first double-blind, sham-controlled trial of this type of intervention.